Small molecule · developed by GSK
Camlipixant (BLU-5937, GSK5464714) is an orally administered agent studied in refractory chronic cough and in healthy subjects.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05600777 | Phase 3 | Cough | Active not recruiting | GSK |
| NCT06497517 | Phase 1 | Cough | Completed | GSK |
| NCT06222892 | Phase 1 | Cough | Completed | GSK |
| NCT05244759 | Phase 1 | Healthy | Completed | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CoughRefractory Chronic CoughHealthy
Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →